Avaliação Da Toxicidade Financeira (Facitcost) De Pacientes Com Câncer No Sul Do Brasil

Abstract

Objetivo: avaliar a toxicidade financeira e correlacionar o escore total com as características sociodemográficas e clínicas de pacientes com câncer assistidos em instituições pública e privada. Método: estudo transversal descritivo, realizado entre setembro de 2018 a janeiro de 2020 com 126 pacientes em tratamento quimioterápico no estado do Paraná, Brasil. Utilizou-se instrumento sociodemográfico e clínico e COmprehensive Score for financial Toxicity; para análise, o teste t de Student e Scoring Guidelines. Resultados: o escore médio da toxicidade financeira na amostra da instituição pública foi de 16,33, na privada de 24,02. Unindo as amostras, o escore médio foi de 18,95. Ao realizar correlação, verificou-se significância estatística com a renda na instituição pública (p-valor=0,002); na instituição privada, presença de comorbidade (p-valor=0,003) e uso de medicamentos (p-valor=0,042). Conclusão: reconhecer a toxicidade financeira como evento adverso auxiliará os profissionais num plano assistencial de acordo com as condições do paciente.

Financial toxicity in people with chronic kidney disease undergoing hemodialysis treatment

“…With regard to lifestyle, among participants in this study with moderate and high FT levels, more than half used continuous medication. Similar data was found in a study ( 6 ) with people with cancer, which found that, of the total number of participants, 60.32% used frequent medication.…”

“…With regard to family income in this study, a quarter of the participants had an income between one and two minimum wages, a value that can show FT, even though care is provided by the public health system. Another study carried out in Brazil with people with cancer identified that the lower the purchasing power, the higher the FT ( 6 ) .…”

“…FT degree in this study may be related to the fact that 78.9% of the sample received treatment through SUS. In the study carried out with people with cancer in Brazil ( 6 ) , it was evidenced that participants assisted by health insurance and/or who paid for treatment privately had higher mean COST scores, indicating greater financial well-being than those assisted by SUS.…”

“…Similar data were obtained in a study with people with DM, in which women with health care paid for by the government, aged between 45 and 59 years, without employment and with low education, had a worse COST score (P <0.01) ( 23 ) . Income of up to one minimum wage was also a factor for worsening FT in a study in people undergoing chemotherapy treatment ( 6 ) .…”

“…FT is measured using the COmprehensive Score for financial Toxicity (COST) instrument from the Functional Assessment of Chronic Illness Therapy (FACIT) group. The COST was validated in Brazil ( 6 ) in a survey conducted with patients with cancer. Another study ( 7 ) validated the COST among patients with chronic disease and demonstrated that the instrument has the potential to be used in populations other than those with cancer to assess FT in diseases such as CKD.…”